Your session is about to expire
← Back to Search
Venetoclax + Inotuzumab for Acute Lymphoblastic Leukemia
Study Summary
This trial is studying how well venetoclax and inotuzumab ozogamicin work in combination in treating patients with acute lymphoblastic leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can care for myself but may not be able to do active work.I haven't taken strong CYP3A4 inhibitors or inducers in the last week.I have had hepatitis C but my current viral load is undetectable.I am 18 years old or older.I have had HSCT or CAR-T therapy and meet specific criteria.My liver and kidney functions are within the required range.I cannot take venetoclax by mouth due to absorption issues.I have a history of severe liver disease.I have been treated with inotuzumab ozogamicin before.I have symptoms from brain or spinal cord involvement.I haven't had chemotherapy for ALL within 2 weeks before starting the study drugs, except for certain allowed medications.I am HIV-positive, on treatment, and my viral load has been undetectable for 6 months.I do not have any severe ongoing health or mental health conditions.I can understand and sign the consent form.My cancer has returned or didn't respond after at least one chemotherapy treatment.I have recovered from side effects of previous cancer treatments, except for hair loss.My leukemia is confirmed to be CD22 positive.I have chronic hepatitis B but my viral load is undetectable.I have been treated with venetoclax for a relapse before.
- Group 1: Venetoclax + Inotuzumab Ozogamicin with Dexamethasone
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you detail any other research conducted on Venetoclax?
"Currently, there are 770 Venetoclax studies in progress with 170 of them being Phase 3 trials. While the majority are situated in Edmonton, Alberta, a total of 25 871 locations spanning the globe are taking part in these investigations."
Are there any vacancies within this clinical trial?
"Affirmative. Clinicaltrials.gov substantiates that this clinical investigation is currently recruiting, first posted on September 24th 2021 and most recently updated October 31st 2022. The trial aims to enlist 26 participants from 2 medical sites."
Has Venetoclax received official sanction by the Food and Drug Administration?
"The safety of venetoclax was assessed as a 1 on our Power team's scale, due to the limited evidence available during this early-stage trial."
What maladies is Venetoclax therapeutically employed to address?
"Venetoclax is traditionally prescribed for ophthalmic and sympathetic diseases, but it can also be used to treat branch retinal vein occlusion, macular edema, and communicable maladies."
What is the current enrollment size of this clinical experiment?
"Affirmative. As indicated on clinicaltrials.gov, this medical trial is still enrolling candidates with its initial posting being made on September 24th 2021 and the last update happening at the end of October in 2022. The recruitment quota set by researchers includes 26 patients from two distinct sites."
Share this study with friends
Copy Link
Messenger